Solara Active Pharma Sciences · NSE: SOLARA · BSE: 541540
Q2 FY25 results · Jul–Sep 2024
Solara Active Pharma Sciences reported revenue from operations of ₹346.95 crore (down 18.4% from Q2 FY24) and net profit of ₹8.01 crore for Q2 FY25 (Jul–Sep 2024), on a consolidated basis.
| Item | Q2 FY25 | Q2 FY24 | YoY | Q1 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 346.95 | 425.24 | −18.4% | 363.49 | −4.6% |
| Other income | 0.32 | 1.18 | −72.9% | 0.56 | −42.9% |
| Total income | 347.27 | 426.42 | −18.6% | 364.05 | −4.6% |
| Profit before tax | 8.01 | (17.06) | Turned profit | (13.46) | Turned profit |
| Net profit for the period | 8.01 | (17.06) | Turned profit | (13.46) | Turned profit |
| EPS, basic (₹) | 2.54 | (4.77) | not comparable | (3.50) | Turned profit |
| Net margin (%) | 2.3 | -4.0 | -3.7 |
| Item | Q2 FY25 | Q2 FY24 | YoY | Q1 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 346.95 | 425.24 | −18.4% | 363.49 | −4.6% |
| Other income | 0.32 | 1.23 | −74.0% | 1.38 | −76.8% |
| Total income | 347.27 | 426.47 | −18.6% | 364.87 | −4.8% |
| Profit before tax | 8.02 | (15.26) | Turned profit | (12.32) | Turned profit |
| Net profit for the period | 8.02 | (15.26) | Turned profit | (12.32) | Turned profit |
| EPS, basic (₹) | 2.11 | (4.24) | not comparable | (3.20) | Turned profit |
| Net margin (%) | 2.3 | -3.6 | -3.4 |
Consolidated
- Filed with BSE
- 04 Nov 2024, 13:25 IST
- Board meeting
- 21 Oct 2024
- Period
- 01 Jul 2024 to 30 Sep 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 04 Nov 2024, 13:25 IST
- Board meeting
- 21 Oct 2024
- Period
- 01 Jul 2024 to 30 Sep 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE